---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105022"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:06:54.170341+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial

## Summary
- Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.
- Cash, equivalents and investments $656.8M, expected to fund operations into 2029.
- RLY-2608 + fulvestrant Phase 1b data: 10.3-month median PFS, 39% ORR in PI3Kα-mutated HR+/HER2- mBC.
- Initiated Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant vs capivasertib + fulvestrant.
- R&D expenses decreased to $63.9M from $92.0M due to streamlining and license agreement.

## SEC filing metadata
- accession: 0000950170-25-105022
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/0000950170-25-105022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/rlay-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105022
- JSON: https://secwatch.observer/filing/0000950170-25-105022.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.